Cancer treatments can work, but the same factors that help them eradicate tumors may also accelerate aging processes in the body — especially the brain. New research explores.
Chemo brain occurs during cancer treatment, and it may last for a long time after the treatment is over.
People experiencing it report a loss of quality in cognitive abilities, which interferes with their daily lives.
In a new study, researchers from the University of California, Los Angeles (UCLA) delve deeper into this issue by working with women who went through breast cancer treatment in the past.
These women, they saw, present markers of biological aging associated with decreased cognitive function.
The study authors explain that the treatments that doctors prescribe for breast cancer can affect a person’s long-term health, leading not just to cognitive problems, but also to persistent fatigue as well as physical pain.
Some chemotherapy agents, as well as radiation therapy, destroy cancer by damaging the DNA of cancer cells. However, this can also damage the DNA of surrounding healthy cells, thereby accelerating aging processes.
The team — conducted by Judith Carroll, an associate professor of psychiatry at the UCLA Cousins Center for Psychoneuroimmunology — worked with 94 women who had had a form of breast cancer treatment 3–6 years before the start of the study.
They analyzed markers of biological aging, such as high DNA damage levels, reduced telomerase activity, and shortened telomeres in blood cells. Telomeres are the “caps” that protect cell DNA, and telomerase is an enzyme that helps maintain telomere length.
As telomeres become shorter and shorter, this eventually sends a signal that the cell is aging and will soon die. Therefore, telomerase activity can be an indicator of how well the body is able to maintain cell health.
The researchers revealed that study participants who had high levels of DNA damage and low telomerase activity tended to also score lower on tests assessing executive function.
Furthermore, those with signs of low telomerase activity also showed poor attention and a decline in motor (movement) speed.
“These findings,” says Carroll, “are important because they provide further information about what might be happening after cancer treatment that impacts cognitive decline in some individuals.”
“This information […] may lead to new interventions to prevent these cognitive declines,” she adds.
Carroll also believes that establishing the connection between markers of biological aging and signs of cognitive problems following cancer treatment could pave the way to future studies addressing this issue.
“The work is novel by identifying key factors in biological aging and connecting them to cognitive function, which initiates new avenues of research.”